NPC1 and Alzheimer disease: Additionally, while biochemical findings of the present study were compared to healthy controls, the absence of clinical control groups (e.g., sporadic AD patients or heterozygous NPC1 carriers without AD) makes it difficult to determine whether the observed effects are specific to NPC1‐related AD or more generalizable.